Senior source denies any merger discussions between AstraZeneca and Bristol Myers Squibb, stating there is no deal and never was a deal to be done.
Reports indicate that preliminary talks were held but have since ended or never progressed.
Both companies have declined to comment on the status of the talks.
Initial speculation about a $400 billion merger led to significant stock movements but subsequent reports have cooled the merger buzz.
Sources:
AstraZeneca stock falls as investors balk at reported Bristol Myers tie-up
AstraZeneca and Bristol Myers Squibb merger talks denied - Quartz
Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal ...
AstraZeneca investors balk at prospect of $400 billion Bristol Myers ...
AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'
FTSE 100 dips as AstraZeneca slides on Bristol Myers tie- ...
AstraZeneca falls to third-largest UK company amid US merger talks
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
AstraZeneca, Bristol Myers Squibb Held Tie-Up Talks, FT ...
AstraZeneca-Bristol Myers' $400B Merger Buzz Cools After ...
AstraZeneca Shares Drop, Bristol Myers Squibb's Climb After Merger ...
AstraZeneca and Bristol Myers Squibb mull $400 billion deal
Senior Source Denies AstraZeneca and Bristol Myers Deal ...
AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report
AstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb